Pulmonary light chain deposition disease secondary to Sjögren disease: a case report

Read full text
Authors: Xiaotong Xu, Lingjian Wang, Chunsheng Zhou, Lu Zhang, T Zhang, Min Peng, Rui’e Feng, Ji Shi
Cited by: 1
References: 12

Abstract

Pulmonary light chain deposition disease (PLCDD) is a rare disorder characterized by the deposition of immunoglobulin light chains in the lungs, often associated with lymphoplasmacytic proliferative and autoimmune disease such as primary Sjögren disease (pSjD). Due to its rarity, there is currently no established definitive management of PLCDD. In this case report, we present the clinical presentation of a 42-year-old female with a history of pSjD who experienced recurrent hemoptysis over a period of 3 years. Radiological and pathological assessments confirmed pulmonary involvement of light chain deposition disease. Despite initial failure of glucocorticoids and immunosuppressive agents in targeting pSjD, subsequent combination therapy with bortezomib and dexamethasone (BD) resulting in significant clinical and radiological improvement. The successful use of this combination treatment in PLCDD represents a significant breakthrough, highlighting the potential effectiveness of targeted therapies for PLCDD secondary to autoimmune disease.

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes IgG4-Related and Inflammatory Diseases Systemic Lupus Erythematosus Research

Publication details

Journal / source
Frontiers in Immunology
Publisher
Frontiers Media SA
Volume
17
Pages
1747455–1747455
Publication date
16 February 2026
Language
EN